Publications

November 2016
Case

Transformation at Eli Lilly & Co. (A)

By: William R. Kerr and Alexis Brownell

Faced with the imminent loss of 40% of its revenues due to patent expirations, pharma giant Eli Lilly sets out on a dramatic transformation process in 2009. The case considers how Lilly restructured the organization into business areas to aid better decision-making,... View Details

Keywords: Eli Lilly; Restructuring; R＆D; Transformation; Organizational Change and Adaptation; Organizational Structure; Pharmaceutical Industry; Indianapolis

October 2000 (Revised March 2003)
Case

Merck & Company: Evaluating a Drug Licensing Opportunity

By: Richard S. Ruback and David B Krieger

This explores the valuation of an opportunity to license a compound before it enters clinical trials. Describes Merck's decision tree evaluation process is presented. Information required to evaluate a specific licensing opportunity is provided, including the costs of... View Details

Keywords: Decision Making; Cost vs Benefits; Opportunities; Valuation; Outcome or Result; Pharmaceutical Industry

03 Feb 2015
First Look

First Look: February 3

field and other business fields complements the contributions from industrial organization economics (IO). These business fields also offer theoretical and empirical challenges to the IO paradigm, which dominates antitrust analysis. The... View Details

Keywords: Sean Silverthorne

Web

General Management Awards & Honors - Faculty & Research

Regina E. Herzlinger : Named one of the 40 Smartest People in Healthcare by Becker’s Hospital Review in 2014. Regina E. Herzlinger : Received the 2014 Beatrice D. Ellerin Award from the HBS Health Industry Alumni. The prestigious and... View Details

June 2004 (Revised June 2006)
Supplement

Vertex Pharmaceuticals: R&D Portfolio Management (A)

By: Gary P. Pisano, Lee Fleming and Eli Strick

Vertex Pharmaceuticals, Inc., a drug discovery company that recently decided to pursue a vertically integrated business model, chose to build up its clinical development and commercial capabilities and infrastructure. For the first time in its history, Vertex will... View Details

Keywords: Research and Development; Investment Portfolio; Pharmaceutical Industry

15 Dec 2003
Research & Ideas

The New Global Business Manager

now we see new competitors come from smaller countries that, because their home markets are too small to support them, are moving immediately onto the global stage. We also see whole industries that are being born global, particularly the... View Details

Keywords: by Cynthia Churchwell

01 Oct 2001
News

Guy de Chazal: Changing Focus

venture capital with Citicorp. "The industry was much, much smaller in those days," he says. "A few hundred million dollars a year, versus almost a hundred billion today." Drawing on his experience with Morgan Stanley since 1986, he... View Details

Keywords: Deborah Blagg

15 Jan 2013
First Look

First Look: January 15

circumscribe citizen-employees, and they engage in production and trade. But individual corporations are no longer adequate to serve as the primary unit of analysis. Over the years, systems of distributed innovation-so-called business ecosystems-have become... View Details

Keywords: Sean Silverthorne

November 2002
Compilation

Four Principles of Biomedical Ethics: Definitions and Examples

By: Sandra J. Sucher

Introduces four principles of biomedical ethics, excerpted from Principles of Biomedical Ethics, Tom L. Beauchamp and James F. Childress (Oxford University Press, 2001). The principles provide a conceptual framework for the analysis and resolution of moral problems... View Details

Keywords: Framework; Moral Sensibility; Health Care and Treatment; Distribution; Problems and Challenges; Research; Emotions; Management Analysis, Tools, and Techniques; Pharmaceutical Industry; Pharmaceutical Industry

13 Oct 2009
Research & Ideas

7 Lessons for Navigating the Storm

take the global economic crisis, or any other crisis, and turn it into an opportunity to transform your markets and your company? Here are 7 steps to keep your organization focused on winning the depth of the crisis: Step 1: Rethink your View Details

Keywords: by Martha Lagace

November 2020
Case

Valuing Celgene's CVR

By: Benjamin C. Esty and Daniel Fisher

When Bristol-Myers Squibb (BMS) acquired Celgene Corporation in November 2019, Celgene shareholders received cash, BMS stock, and a contingent value right (CVRs) that would pay $9 if the U.S. Food and Drug Administration (FDA) approved three of Celgene’s late stage... View Details

Keywords: Mergers and Acquisitions; Value; Valuation; Judgments; Decision Making; Cash Flow; Financial Instruments; Cognition and Thinking; Pharmaceutical Industry; Pharmaceutical Industry; United States

June 2023
Supplement

Roche: ESG and Access to Healthcare

By: George Serafeim

In May 2022, Roche Group, one of the largest healthcare companies in the world, hosted its first ESG investor event focused exclusively on its efforts to impact access to healthcare. While Roche had recently set an ambitious goal to double the number of patients that... View Details

Web

2022 Reunion Presentations - Alumni

Senior Lecturer Kristin W. Mugford (MBA 1993) + More Info – Less Info Over the last decade, firms have begun to recognize the power of gender diversity and have worked to actively hire and retain more women. While we see improved diversity at junior levels, View Details

Web

Strategy Awards & Honors - Faculty & Research

Outstanding Educator Award for Excellence in MBA/Executive education from the Strategic Management Division of the Academy of Management. Maria P. Roche : Runner-up for the Best Paper in Innovation and Entrepreneurship at the 2024 View Details

31 Jan 2014
News

Body, Heal Thyself

for the development and exclusive use of the mRNA technology to treat cardiovascular, renal, and metabolic diseases as well as cancer. "It is one of the largest-ever initial payments in a pharmaceutical View Details

Keywords: Maureen Harmon; biotech; Health, Social Assistance; Scientific Research and Development Services

November 2005 (Revised March 2006)
Case

Genentech - Capacity Planning

By: Daniel C. Snow, Steven C. Wheelwright and Alison Berkley Wagonfeld

While facilitating a complex clinical approval process over the next two to three years for a family of new cancer drugs, Genentech must develop a long-term capacity plan for a major class of new cancer products. Adding to the complexity and uncertainty is the fact... View Details

Keywords: Factories, Labs, and Plants; Growth and Development Strategy; Management Style; Management Teams; Time Management; Product; Product Development; Business Processes; Performance Capacity; Planning; Risk and Uncertainty; Complexity; Pharmaceutical Industry

October 2021 (Revised October 2022)
Case

The Opioid Settlement and Controversy Over CEO Pay at AmerisourceBergen

By: Suraj Srinivasan and Li-Kuan Ni

In 2020, AmerisourceBergen Corporation, a Fortune 50 company in the drug distribution industry, agreed to settle thousands of lawsuits filed nationwide against the company for its opioid distribution practices that critics alleged had contributed to the nationwide... View Details

12 Nov 2013
First Look

First Look: November 12

GlaxoSmithKline: Sourcing Complex Professional Services Pharmaceutical company GlaxoSmithKline (GSK) uses an innovative new approach to procuring outside legal counsel: it replaces relationship-based selection and law firms' traditional... View Details

Keywords: Sean Silverthorne

April 2011 (Revised April 2015)
Case

Cipla 2011

By: Rohit Deshpande, Sandra J. Sucher and Laura Winig

Dr. Yusuf Hamied, head of the Indian pharma and generics manufacturing company Cipla, is weighing options for how to continue to support the global fight against HIV/AIDS while positioning his company for growth in a changing regulatory landscape. View Details

Keywords: Leadership; Leading Change; Leadership Style; Management Teams; Governance Compliance; Corporate Strategy; Pharmaceutical Industry